Cara Therapeutics doses first patient in Phase 2 trial of Korsuva for pruritus
Cara Therapeutics initiated its Phase 2 clinical trial of Oral Korsuva in patients with pre-dialysis chronic kidney disease. The tablet formulation of Oral Korsuva was engineered using proprietary oral peptide delivery technology, Peptelligence, from Enteris BioPharma, a biotechnology company developing drug products built around its proprietary delivery technologies. A Phase 1 trial in moderate-to-severe CKD Patients demonstrated that exposure levels with Oral Korsuva tablets were approximately equivalent to the exposure level achieved with a 0.5 mcg/kg dose of intravenous CR845. Oral Korsuva is also the subject of a Phase 2 program in chronic pain, a Phase 1 program in hemodialysis chronic kidney disease and a Phase 1 program in chronic liver disease patients. Under the terms of the "Feasibility-to-Licensing" program, Enteris will continue to manufacture the oral tablet formulation of Korsuva, CR845, for current and potential future studies through Phase 2 that Cara Therapeutics elects to pursue. Cara Therapeutics has the opportunity to negotiate a phase 3/ commercial license to the Peptelligence technology for oral CR845 from Enteris at any time.